Innovative Medicine

Innovative Medicine

April 1, 2014

Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy

Research

March 31, 2014

Janssen Expands the EXPLORER Global Cardiovascular Research Program with Three New Studies Evaluating XARELTO® in Patients at Risk for Venous Thromboembolism

Innovative Medicine

March 24, 2014

Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy In Treatment Of Moderate To Severe Plaque Psoriasis

Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab

Innovative Medicine

March 21, 2014

Siltuximab Receives CHMP Positive Opinion for use in the Treatment of Multicentric Castleman’s Disease, a very Rare Blood Disorder

Innovative Medicine

March 20, 2014

Janssen Investigational Treatment for Schizophrenia Shows Positive Efficacy, Delays Relapse

Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy

Innovative Medicine

February 21, 2014

Janssen Initiates CREDENCE Study in Patients with Type 2 Diabetes and Diabetic Nephropathy

Trial Seeks to Examine the Effects of INVOKANA® on the Progression of Diabetic Nephropathy

Innovative Medicine

February 21, 2014

VOKANAMETTM (canagliflozin and metformin fixed dose combination) receives positive CHMP opinion recommending approval in the European Union for the treatment of adults with type 2 diabetes[1]

Innovative Medicine

February 14, 2014

FDA Issues Complete Response Letters for Use of XARELTO® (rivaroxaban) to Reduce the Risk of Secondary Cardiovascular Events and Stent Thrombosis in Patients with Acute Coronary Syndrome

Innovative Medicine

February 12, 2014

IMBRUVICA™ (ibrutinib) Now Approved in the U.S. for Patients with Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy